4.5 Review

Substrate and drug binding sites in LeuT

Journal

CURRENT OPINION IN STRUCTURAL BIOLOGY
Volume 20, Issue 4, Pages 415-422

Publisher

CURRENT BIOLOGY LTD
DOI: 10.1016/j.sbi.2010.05.007

Keywords

-

Funding

  1. NIH [MH083840, GM075936, DA019676, DA013261, GM075026, F32HL091618]
  2. American Heart Association

Ask authors/readers for more resources

LeuT is a member of the neurotransmitter/sodium symporter family, which includes the neuronal transporters for serotonin, norepinephrine, and dopamine. The original crystal structure of LeuT shows a primary leucine-binding site at the center of the protein. LeuT is inhibited by different classes of antidepressants that act as potent inhibitors of the serotonin transporter. The newly determined crystal structures of LeuT-antidepressant complexes provide opportunities to probe drug binding in the serotonin transporter, of which the exact position remains controversial. Structure of a LeuT-tryptophan complex shows an overlapping binding site with the primary substrate site. A secondary substrate binding site was recently identified, where the binding of a leucine triggers the cytoplasmic release of the primary substrate. This two binding site model presents opportunities for a better understanding of drug binding and the mechanism of inhibition for mammalian transporters.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available